<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02665910</url>
  </required_header>
  <id_info>
    <org_study_id>SHR0302-102</org_study_id>
    <nct_id>NCT02665910</nct_id>
  </id_info>
  <brief_title>Multiple Doses Escalation Study of SHR0302 in Rheumatoid Arthritis (RA) Patients</brief_title>
  <official_title>A Phase I, Randomized, Placebo-Controlled, Multiple Doses Escalation Study to Investigate Safety, Pharmacokinetics and Pharmacodynamics of SHR0302 in Patients With RA</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Condition: Rheumatoid Arthritis Intervention: Drug: SHR0302; Drug: SHR0302 placebo comparator
      Phase: Phase 1 Study Type: Interventional Study Design: Treatment, Parallel Assignment,
      Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Randomized
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>May 2016</start_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events and the number of volunteers with adverse events as a measure of safety and tolerability.</measure>
    <time_frame>up to 48 hrs postdose</time_frame>
    <description>Tests will be performed to assess whether the study drug has any potentially adverse effect (laboratory tests on blood and urine for functioning of organs; cardiovascular testing, i.e. of heart and blood circulation). Also, participants will carefully be monitored by medical staff for vital signs, and asked to report any side effect experienced in the course of the study</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The maximum plasma concentration (Cmax) of SHR0302</measure>
    <time_frame>At protocol-specified times up to 48 hrs postdose</time_frame>
    <description>Blood samples are taken on various timepoints to assess the pharmacokinetic parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The area under the plasma concentration-time curve (AUC) of SHR0302</measure>
    <time_frame>At protocol-specified times up to 48 hrs postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2 of SHR0302</measure>
    <time_frame>At protocol-specified times up to 48 hrs postdose</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Pharmacodynamics (PD) parameters of percent and actual change from baseline for a panel of JAK dependent biomarkers</measure>
    <time_frame>At protocol-specified times up to 24 hrs postdose</time_frame>
    <description>To characterize the effects of SHR0302 on mechanism of action-related biomarkers in the blood over time - pharmacodynamics (PD) - in RA.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>SHR0302</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple ascending doses (2, 5, 10, 25 mg), oral tablets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SHR0302 placebo comparator</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Multiple ascending doses (2, 5, 10, 25 mg), oral tablets (matching corresponding study medication)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHR0302</intervention_name>
    <description>Oral tablets (1 mg, 5 mg, 10 mg)</description>
    <arm_group_label>SHR0302</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHR0302 placebo comparator</intervention_name>
    <description>Oral tablets (1 mg, 5 mg, 10 mg) (matching corresponding study medication)</description>
    <arm_group_label>SHR0302 placebo comparator</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female subjects who are 18~70 years of age on the day of signing informed
             consent,

          -  Have a diagnosis of RA meeting the 1987 ACR/EULAR criteria of RA and ACR functional
             class I-III,

          -  Body mass index (BMI = weight/height squared (kg/m2)) within the range of 19 to 30,

          -  Have agreed to not use any anti- rheumatic drug except for study drugs during the
             study period.

        Exclusion Criteria:

          -  Current therapy with any disease modifying anti-rheumatic drug (DMARD), with the
             exception of Methotrexate (MTX), Leflunomide, sulfasalazine, antimalarials, gold
             preparations, penicillamine, which must have discontinued for a period of at least 7
             t1/2s prior to dosing,

          -  Previous RA treatment with DMARDs or drugs with strong immunosuppressive effect in 3
             months prior to dosing (12 months for rituximab or other B cell depleting agents),

          -  Previous therapy with NSAIDs or oral glucocorticoids in 2 weeks before dosing,

          -  Any parenteral (intramuscular or intravenous injection) or intra-articular
             corticosteroids therapy in 4 weeks before dosing,

          -  Previous treatment with interferons in 4 weeks before dosing.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pei Hu, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking Union Medical College Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Xiaofeng Zeng, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking Union Medical College Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chengyu Guan, MD</last_name>
    <phone>15705155015</phone>
    <email>guanchengyu@hrs.com.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pei Hu, PhD</last_name>
      <phone>86-010-69158366</phone>
      <email>pei.hu.pumc@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Pei Hu, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xiaofeng Zeng, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 24, 2016</study_first_submitted>
  <study_first_submitted_qc>January 24, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 28, 2016</study_first_posted>
  <last_update_submitted>April 18, 2016</last_update_submitted>
  <last_update_submitted_qc>April 18, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 19, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

